Bleeding risk and P2Y12 inhibitors in all-comer patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention: a single-centre cohort study
Authors:
- Mia Ravn JacobsenMJMia Ravn Jacobsen
- Reza JabbariRJReza Jabbari
- Thomas EngstrømTEThomas Engstrøm
- Erik Lerkevang GroveEGErik Lerkevang Grove
- Charlotte GlingeCGCharlotte Glinge
- Frants PedersenFPFrants Pedersen
- Lene HolmvangLHLene Holmvang
- Lars KøberLKLars Køber
- Michael MaengMMMichael Maeng
- Karsten VeienKVKarsten Veien
Open Access
- 4 July 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 9 (7) , 617-626
Abstract
Aims: To characterize and follow patients with ST-segment elevation myocardial infarction (STEMI) at high bleeding risk (HBR) according to the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score, and to examine the use of P2Y12 inhibitors and the subsequent risk of major adverse cardiovascular events (MACE) and bleeding. Methods and results: This single-centre cohort study included 6179 consecutive STEMI patients who underwent percutaneous coronary intervention (PCI) at Copenhagen University Hospital, Rigshospitalet, between 2009 and 2016. Individual linkage to nationwide registries was conducted to obtain information on diagnoses, claimed drugs, and vital status. Of the 5532 (89.5%) patients with available PRECISE-DAPT scores, 33.0% were at HBR and more often elderly and female with more comorbidities than non-HBR patients. One-year cumulative incidence rates per 100 person-years were 8.7 and 2.1 for major bleeding and 36.8 and 8.3 for MACE in HBR and non-HBR patients, respectively. Among the 4749 (85.8%) patients who survived and collected a P2Y12 inhibitor ≤7 days from discharge, 68.2% of HBR patients were treated with ticagrelor or prasugrel and 31.8% with clopidogrel, while 18.2% non-HBR patients were treated with clopidogrel. Adherence was high for all (>75% days coverage). The risk of MACE was lower in ticagrelor- and prasugrel-treated patients than in clopidogrel-treated patients without differences in major bleeding. Conclusion: One-third of PCI-treated all-comer patients with STEMI were at HBR according to the PRECISE-DAPT score and were more often treated with potent P2Y12 inhibitors instead of clopidogrel. Thus, ischaemic risk may be weighted over bleeding risk in STEMI patients at HBR.Keywords
Funding Information
- Novo Nordisk Foundation (0071947)
- Gangstedfonden (R625-A41879)
This publication has 22 references indexed in Scilit:
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTSEuropean Heart Journal, 2017
- Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trialsThe Lancet, 2017
- Evaluation of algorithms for registry-based detection of acute myocardial infarction following percutaneous coronary interventionClinical Epidemiology, 2016
- Impact of renal insufficiency on mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary interventionBMC Cardiovascular Disorders, 2014
- Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of CardiologyEuropean Heart Journal, 2011
- Mortality and morbidity following a major bleed in a registry population with acute ST elevation myocardial infarctionJournal of Thrombosis and Thrombolysis, 2010
- Initiation and persistence with clopidogrel treatment after acute myocardial infarction – a nationwide studyBritish Journal of Clinical Pharmacology, 2008
- Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary SyndromesCirculation, 2006
- A Comparison of the Clinical Impact of Bleeding Measured by Two Different Classifications Among Patients With Acute Coronary SyndromesJACC, 2006
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976